nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A dietary pattern derived to correlate with estrogens and risk of postmenopausal breast cancer
|
Fung, Teresa T. |
|
2012 |
132 |
3 |
p. 1157-1162 |
artikel |
2 |
A gene transcription signature of obesity in breast cancer
|
Creighton, Chad J. |
|
2011 |
132 |
3 |
p. 993-1000 |
artikel |
3 |
A plea for the biopsy marker: how, why and why not clipping after breast biopsy?
|
Thomassin-Naggara, Isabelle |
|
2011 |
132 |
3 |
p. 881-893 |
artikel |
4 |
Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes
|
Menéndez, Mireia |
|
2011 |
132 |
3 |
p. 979-992 |
artikel |
5 |
Biopsy sampling of breast lesions: comparison of core needle- and vacuum-assisted breast biopsies
|
Lacambra, Maribel D. |
|
2011 |
132 |
3 |
p. 917-923 |
artikel |
6 |
CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer
|
Marmé, Frederik |
|
2011 |
132 |
3 |
p. 819-831 |
artikel |
7 |
Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members
|
Thomassen, Mads |
|
2011 |
132 |
3 |
p. 1009-1023 |
artikel |
8 |
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
|
Esserman, Laura J. |
|
2011 |
132 |
3 |
p. 1049-1062 |
artikel |
9 |
Clinical and biomarker predictors of side effects from tamoxifen
|
Lorizio, Wendy |
|
2011 |
132 |
3 |
p. 1107-1118 |
artikel |
10 |
Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer
|
Varga, Zsuzsanna |
|
2011 |
132 |
3 |
p. 925-935 |
artikel |
11 |
Comparative gene expression analysis in mouse models for identifying critical pathways in mammary gland development
|
Zhao, Hongbo |
|
2011 |
132 |
3 |
p. 969-977 |
artikel |
12 |
Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer
|
Domagala, Pawel |
|
2011 |
132 |
3 |
p. 937-945 |
artikel |
13 |
Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2
|
Ma, Xinrong |
|
2011 |
132 |
3 |
p. 1001-1008 |
artikel |
14 |
Fruit and vegetables consumption and breast cancer risk: the EPIC Italy study
|
Masala, Giovanna |
|
2012 |
132 |
3 |
p. 1127-1136 |
artikel |
15 |
Gamma-ray-induced mutagen sensitivity and risk of sporadic breast cancer in young women: a case–control study
|
Wang, Li-E |
|
2012 |
132 |
3 |
p. 1147-1155 |
artikel |
16 |
Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents
|
Kadra, Gais |
|
2011 |
132 |
3 |
p. 1035-1047 |
artikel |
17 |
Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy
|
Koppelmans, Vincent |
|
2011 |
132 |
3 |
p. 1099-1106 |
artikel |
18 |
Introduction to special issue Translational goals of neoadjuvant therapy
|
Glück, Stefan |
|
2012 |
132 |
3 |
p. 773 |
artikel |
19 |
Ipsilateral hemodialysis access after axillary dissection for breast cancer
|
Olsha, Oded |
|
2012 |
132 |
3 |
p. 1173-1176 |
artikel |
20 |
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
|
Luporsi, Elisabeth |
|
2011 |
132 |
3 |
p. 895-915 |
artikel |
21 |
Lack of caveolin-1 (P132L) somatic mutations in breast cancer
|
Ferraldeschi, Roberta |
|
2012 |
132 |
3 |
p. 1185-1186 |
artikel |
22 |
Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial)
|
Lin, Cheryl |
|
2011 |
132 |
3 |
p. 871-879 |
artikel |
23 |
Mammographic density, parity and age at first birth, and risk of breast cancer: an analysis of four case–control studies
|
Woolcott, Christy G. |
|
2012 |
132 |
3 |
p. 1163-1171 |
artikel |
24 |
MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide
|
Okishiro, Masatsugu |
|
2011 |
132 |
3 |
p. 947-953 |
artikel |
25 |
NQO1 expression correlates inversely with NFκB activation in human breast cancer
|
Jamshidi, Maral |
|
2011 |
132 |
3 |
p. 955-968 |
artikel |
26 |
Obstetric history and mammographic density: a population-based cross-sectional study in Spain (DDM-Spain)
|
Lope, Virginia |
|
2012 |
132 |
3 |
p. 1137-1146 |
artikel |
27 |
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)
|
Zambetti, Milvia |
|
2011 |
132 |
3 |
p. 843-851 |
artikel |
28 |
Pathologic complete response after neoadjuvant therapy of breast cancer: pitfalls and shortcomings
|
Minckwitz, Gunter von |
|
2012 |
132 |
3 |
p. 779-780 |
artikel |
29 |
Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo
|
Ramaswamy, B. |
|
2011 |
132 |
3 |
p. 1063-1072 |
artikel |
30 |
Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
|
Kaklamani, Virginia G. |
|
2011 |
132 |
3 |
p. 833-842 |
artikel |
31 |
Primary and secondary angiosarcomas of the breast: a single institution experience
|
Fraga-Guedes, Conceição |
|
2011 |
132 |
3 |
p. 1081-1088 |
artikel |
32 |
RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data
|
Győrffy, Balázs |
|
2011 |
132 |
3 |
p. 1025-1034 |
artikel |
33 |
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40)
|
Minckwitz, Gunter von |
|
2011 |
132 |
3 |
p. 863-870 |
artikel |
34 |
SerpinB3, a new prognostic tool in breast cancer patients treated with neoadjuvant chemotherapy
|
Collie-Duguid, Elaina S. R. |
|
2011 |
132 |
3 |
p. 807-818 |
artikel |
35 |
The efficacy and safety of neoadjuvant chemotherapy +/− letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial
|
Mohammadianpanah, Mohammad |
|
2011 |
132 |
3 |
p. 853-861 |
artikel |
36 |
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers
|
Laitman, Yael |
|
2011 |
132 |
3 |
p. 1119-1126 |
artikel |
37 |
TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab
|
Glück, Stefan |
|
2011 |
132 |
3 |
p. 781-791 |
artikel |
38 |
Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival—a retrospective multi-centre cohort study
|
Schwentner, L. |
|
2011 |
132 |
3 |
p. 1073-1080 |
artikel |
39 |
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
|
Ono, Makiko |
|
2011 |
132 |
3 |
p. 793-805 |
artikel |
40 |
US follow-up protocol in concordant benign result after US-guided 14-gauge core needle breast biopsy
|
Youk, Ji Hyun |
|
2012 |
132 |
3 |
p. 1089-1097 |
artikel |
41 |
Using neoadjuvant therapy for breast cancer in clinical practice: when and how?
|
Tripathy, Debu |
|
2012 |
132 |
3 |
p. 775-777 |
artikel |
42 |
Why do women accept to undergo a nipple sparing mastectomy or to reconstruct the nipple areola complex when nipple sparing mastectomy is not possible?
|
Didier, F. |
|
2012 |
132 |
3 |
p. 1177-1184 |
artikel |